Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...
The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study | The FDA has put a clinical hold on a Tenaya ...
Scientists have reversed diabetic heart failure with a genetic therapy in mice and a miniature human hearts made from stem ...
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has ...
Researchers discovered that a longevity gene from centenarians can reverse heart damage linked to progeria, suggesting a new approach to treating rapid and age-related heart aging. A major advancement ...
20hon MSN
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.
In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...
Tenaya Therapeutics said on Friday the U.S. Food and Drug Administration has placed a clinical hold on its trial of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback